SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Bayer AG (ETR: BAYGN) delivered a robust performance in the third quarter of 2025, reporting a 138% surge in core earnings per share to €0.57, up from €0.24 a year earlier. The German healthcare and agriculture giant attributed the growth to improved margins in its Crop Science division and continued momentum in new pharmaceuticals, despite currency headwinds and litigation-related payouts affecting cash flow.
Group sales rose 1% on a currency- and portfolio-adjusted basis to €9.7 billion, though reported revenue slipped 3% due to a €0.4 billion foreign exchange impact. EBITDA before special items jumped 21% to €1.5 billion, driven primarily by stronger results in Crop Science. However, free cash flow declined to €0.6 billion from €1.1 billion, reflecting higher litigation expenses. Net financial debt decreased 7% to €32.7 billion.
Crop Science, Bayer’s largest business unit, posted 1% growth (cpa) to €3.9 billion, supported by a 22% rise in corn seed and traits from increased U.S. planting and Latin American demand. Non-glyphosate herbicides rose 7%, while soybean and cotton seed sales declined due to regulatory setbacks. The division’s EBITDA margin climbed to 4.5% from 0.9%.
Pharmaceuticals reported flat sales at €4.3 billion, as soaring demand for Nubeqa (+56%) and Kerendia (+85%) offset a 31% drop in Xarelto amid generic competition. Eylea sales fell 11%, though its 8 mg version accounted for 27% of total revenue. Divisional EBITDA fell 5% to €1 billion.
Consumer Health grew 2% (cpa) to €1.4 billion, led by strong dermatology and digestive health segments.
For the first nine months of 2025, Bayer posted €34.1 billion in sales (+1% cpa) and €4.29 core EPS (+7%). The company reaffirmed its 2025 outlook, targeting sales between €46–48 billion and EBITDA before special items of €9.7–10.2 billion.
